http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 09 Jun 2026 09:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/REPROCELL+Receives+Commercialization+Award+from+Maryland+Stem+Cell+Research+Fund+to+Advance+Universal%2C+Hypoimmune+iPSC+Platforms/26621329.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> (TYO: 4978) today announced that it has received a competitive Commercialization Award from the <span>Maryland Stem Cell Research Fund</span> (MSCRF). The funding will support the development of clinical grade, hypoimmune induced pluripotent stem cell (iPSC) seed stocks for clinical applications. The award is part of MSCRF's latest funding cycle dedicated to accelerating regenerative medicine technologies and stem cell-based therapies across <location value="LS/us.md" idsrc="xmltag.org" >Maryland</location>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/REPROCELL+Receives+Commercialization+Award+from+Maryland+Stem+Cell+Research+Fund+to+Advance+Universal%2C+Hypoimmune+iPSC+Platforms/26621329.html Tue, 09 Jun 2026 09:00:00 -0400 4978 A.04740540 O.05487715 O.30693798 http://www.streetinsider.com/Press+Releases/REPROCELL+Receives+Commercialization+Award+from+Maryland+Stem+Cell+Research+Fund+to+Advance+Universal%2C+Hypoimmune+iPSC+Platforms/26621329.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> (TYO: 4978) today announced that it has received a competitive Commercialization Award from the <span>Maryland Stem Cell Research Fund</span> (MSCRF). The funding will support the development of clinical grade, hypoimmune induced pluripotent stem cell (iPSC) seed stocks for clinical applications. The award is part of MSCRF's latest funding cycle dedicated to accelerating regenerative medicine technologies and stem cell-based therapies across <location value="LS/us.md" idsrc="xmltag.org" >Maryland</location>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/REPROCELL+Receives+Commercialization+Award+from+Maryland+Stem+Cell+Research+Fund+to+Advance+Universal%2C+Hypoimmune+iPSC+Platforms/26621329.html Tue, 09 Jun 2026 09:00:00 -0400 4978 A.04740540 O.05487715 O.30693798 http://www.streetinsider.com/Press+Releases/REPROCELL+Receives+Commercialization+Award+from+Maryland+Stem+Cell+Research+Fund+to+Advance+Universal%2C+Hypoimmune+iPSC+Platforms/26621329.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> (TYO: 4978) today announced that it has received a competitive Commercialization Award from the <span>Maryland Stem Cell Research Fund</span> (MSCRF). The funding will support the development of clinical grade, hypoimmune induced pluripotent stem cell (iPSC) seed stocks for clinical applications. The award is part of MSCRF's latest funding cycle dedicated to accelerating regenerative medicine technologies and stem cell-based therapies across <location value="LS/us.md" idsrc="xmltag.org" >Maryland</location>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/REPROCELL+Receives+Commercialization+Award+from+Maryland+Stem+Cell+Research+Fund+to+Advance+Universal%2C+Hypoimmune+iPSC+Platforms/26621329.html Tue, 09 Jun 2026 09:00:00 -0400 4978 A.04740540 O.05487715 O.30693798 http://www.streetinsider.com/Press+Releases/REPROCELL+Receives+Commercialization+Award+from+Maryland+Stem+Cell+Research+Fund+to+Advance+Universal%2C+Hypoimmune+iPSC+Platforms/26621329.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> (TYO: 4978) today announced that it has received a competitive Commercialization Award from the <span>Maryland Stem Cell Research Fund</span> (MSCRF). The funding will support the development of clinical grade, hypoimmune induced pluripotent stem cell (iPSC) seed stocks for clinical applications. The award is part of MSCRF's latest funding cycle dedicated to accelerating regenerative medicine technologies and stem cell-based therapies across <location value="LS/us.md" idsrc="xmltag.org" >Maryland</location>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/REPROCELL+Receives+Commercialization+Award+from+Maryland+Stem+Cell+Research+Fund+to+Advance+Universal%2C+Hypoimmune+iPSC+Platforms/26621329.html Tue, 09 Jun 2026 09:00:00 -0400 4978 A.04740540 O.05487715 O.30693798 http://www.streetinsider.com/PRNewswire/REPROCELL+Receives+Commercialization+Award+from+Maryland+Stem+Cell+Research+Fund+to+Advance+Universal%2C+Hypoimmune+iPSC+Platforms/26621329.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> (TYO: 4978) today announced that it has received a competitive Commercialization Award from the <span>Maryland Stem Cell Research Fund</span> (MSCRF). The funding will support the development of clinical grade, hypoimmune induced pluripotent stem cell (iPSC) seed stocks for clinical applications. The award is part of MSCRF's latest funding cycle dedicated to accelerating regenerative medicine technologies and stem cell-based therapies across <location value="LS/us.md" idsrc="xmltag.org" >Maryland</location>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/REPROCELL+Receives+Commercialization+Award+from+Maryland+Stem+Cell+Research+Fund+to+Advance+Universal%2C+Hypoimmune+iPSC+Platforms/26621329.html Tue, 09 Jun 2026 09:00:00 -0400 4978 A.04740540 O.05487715 O.30693798 http://www.streetinsider.com/PRNewswire/REPROCELL+Receives+Commercialization+Award+from+Maryland+Stem+Cell+Research+Fund+to+Advance+Universal%2C+Hypoimmune+iPSC+Platforms/26621329.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> (TYO: 4978) today announced that it has received a competitive Commercialization Award from the <span>Maryland Stem Cell Research Fund</span> (MSCRF). The funding will support the development of clinical grade, hypoimmune induced pluripotent stem cell (iPSC) seed stocks for clinical applications. The award is part of MSCRF's latest funding cycle dedicated to accelerating regenerative medicine technologies and stem cell-based therapies across <location value="LS/us.md" idsrc="xmltag.org" >Maryland</location>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/REPROCELL+Receives+Commercialization+Award+from+Maryland+Stem+Cell+Research+Fund+to+Advance+Universal%2C+Hypoimmune+iPSC+Platforms/26621329.html Tue, 09 Jun 2026 09:00:00 -0400 4978 A.04740540 O.05487715 O.30693798 http://www.streetinsider.com/PRNewswire/REPROCELL+Receives+Commercialization+Award+from+Maryland+Stem+Cell+Research+Fund+to+Advance+Universal%2C+Hypoimmune+iPSC+Platforms/26621329.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> (TYO: 4978) today announced that it has received a competitive Commercialization Award from the <span>Maryland Stem Cell Research Fund</span> (MSCRF). The funding will support the development of clinical grade, hypoimmune induced pluripotent stem cell (iPSC) seed stocks for clinical applications. The award is part of MSCRF's latest funding cycle dedicated to accelerating regenerative medicine technologies and stem cell-based therapies across <location value="LS/us.md" idsrc="xmltag.org" >Maryland</location>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/REPROCELL+Receives+Commercialization+Award+from+Maryland+Stem+Cell+Research+Fund+to+Advance+Universal%2C+Hypoimmune+iPSC+Platforms/26621329.html Tue, 09 Jun 2026 09:00:00 -0400 4978 A.04740540 O.05487715 O.30693798 http://www.streetinsider.com/PRNewswire/REPROCELL+Receives+Commercialization+Award+from+Maryland+Stem+Cell+Research+Fund+to+Advance+Universal%2C+Hypoimmune+iPSC+Platforms/26621329.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> (TYO: 4978) today announced that it has received a competitive Commercialization Award from the <span>Maryland Stem Cell Research Fund</span> (MSCRF). The funding will support the development of clinical grade, hypoimmune induced pluripotent stem cell (iPSC) seed stocks for clinical applications. The award is part of MSCRF's latest funding cycle dedicated to accelerating regenerative medicine technologies and stem cell-based therapies across <location value="LS/us.md" idsrc="xmltag.org" >Maryland</location>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/REPROCELL+Receives+Commercialization+Award+from+Maryland+Stem+Cell+Research+Fund+to+Advance+Universal%2C+Hypoimmune+iPSC+Platforms/26621329.html Tue, 09 Jun 2026 09:00:00 -0400 4978 A.04740540 O.05487715 O.30693798 http://www.streetinsider.com/Press+Releases/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html <div class="xn-content"> <p class="prntac"><i>Integrated Workflow Including Clinical Seed Production </i><i>and StemEdit Gene Editing Services</i></p><p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its <span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> compliant <span>Good Manufacturing Practice (GMP) Master Cell Bank</span> (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its <location value="LU/us.md.bellle" idsrc="xmltag.org" >Beltsville, Maryland</location> facility, <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> now offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=1677481646&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fclinical-stem-cell-services%2Fgmp-ipsc-production&amp;a=StemRNA%E2%84%A2+clinical+seed+iPSC+manufacturing" target="_blank" rel="nofollow">StemRNA™ clinical seed iPSC manufacturing</a> and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=2696405221&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fgene-editing-services%2Fstemedit%2Fcase-studies&amp;a=StemEdit+gene+editing" target="_blank" rel="nofollow">StemEdit gene editing</a> to <a http://www.streetinsider.com/Press+Releases/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html Tue, 03 Mar 2026 09:00:00 -0400 4978 A.04740540 A.06822034 A.31066700 O.05487715 O.20026344 O.22422661 O.30693798 http://www.streetinsider.com/Press+Releases/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html <div class="xn-content"> <p class="prntac"><i>Integrated Workflow Including Clinical Seed Production </i><i>and StemEdit Gene Editing Services</i></p><p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its <span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> compliant <span>Good Manufacturing Practice (GMP) Master Cell Bank</span> (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its <location value="LU/us.md.bellle" idsrc="xmltag.org" >Beltsville, Maryland</location> facility, <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> now offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=1677481646&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fclinical-stem-cell-services%2Fgmp-ipsc-production&amp;a=StemRNA%E2%84%A2+clinical+seed+iPSC+manufacturing" target="_blank" rel="nofollow">StemRNA™ clinical seed iPSC manufacturing</a> and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=2696405221&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fgene-editing-services%2Fstemedit%2Fcase-studies&amp;a=StemEdit+gene+editing" target="_blank" rel="nofollow">StemEdit gene editing</a> to <a http://www.streetinsider.com/Press+Releases/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html Tue, 03 Mar 2026 09:00:00 -0400 4978 A.04740540 A.06822034 A.31066700 O.05487715 O.20026344 O.22422661 O.30693798 http://www.streetinsider.com/Press+Releases/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html <div class="xn-content"> <p class="prntac"><i>Integrated Workflow Including Clinical Seed Production </i><i>and StemEdit Gene Editing Services</i></p><p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its <span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> compliant <span>Good Manufacturing Practice (GMP) Master Cell Bank</span> (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its <location value="LU/us.md.bellle" idsrc="xmltag.org" >Beltsville, Maryland</location> facility, <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> now offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=1677481646&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fclinical-stem-cell-services%2Fgmp-ipsc-production&amp;a=StemRNA%E2%84%A2+clinical+seed+iPSC+manufacturing" target="_blank" rel="nofollow">StemRNA™ clinical seed iPSC manufacturing</a> and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=2696405221&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fgene-editing-services%2Fstemedit%2Fcase-studies&amp;a=StemEdit+gene+editing" target="_blank" rel="nofollow">StemEdit gene editing</a> to <a http://www.streetinsider.com/Press+Releases/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html Tue, 03 Mar 2026 09:00:00 -0400 4978 A.04740540 A.06822034 A.31066700 O.05487715 O.20026344 O.22422661 O.30693798 http://www.streetinsider.com/Press+Releases/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html <div class="xn-content"> <p class="prntac"><i>Integrated Workflow Including Clinical Seed Production </i><i>and StemEdit Gene Editing Services</i></p><p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its <span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> compliant <span>Good Manufacturing Practice (GMP) Master Cell Bank</span> (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its <location value="LU/us.md.bellle" idsrc="xmltag.org" >Beltsville, Maryland</location> facility, <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> now offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=1677481646&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fclinical-stem-cell-services%2Fgmp-ipsc-production&amp;a=StemRNA%E2%84%A2+clinical+seed+iPSC+manufacturing" target="_blank" rel="nofollow">StemRNA™ clinical seed iPSC manufacturing</a> and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=2696405221&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fgene-editing-services%2Fstemedit%2Fcase-studies&amp;a=StemEdit+gene+editing" target="_blank" rel="nofollow">StemEdit gene editing</a> to <a http://www.streetinsider.com/Press+Releases/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html Tue, 03 Mar 2026 09:00:00 -0400 4978 A.04740540 A.06822034 A.31066700 O.05487715 O.20026344 O.22422661 O.30693798 http://www.streetinsider.com/Press+Releases/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html <div class="xn-content"> <p class="prntac"><i>Integrated Workflow Including Clinical Seed Production </i><i>and StemEdit Gene Editing Services</i></p><p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its <span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> compliant <span>Good Manufacturing Practice (GMP) Master Cell Bank</span> (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its <location value="LU/us.md.bellle" idsrc="xmltag.org" >Beltsville, Maryland</location> facility, <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> now offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=1677481646&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fclinical-stem-cell-services%2Fgmp-ipsc-production&amp;a=StemRNA%E2%84%A2+clinical+seed+iPSC+manufacturing" target="_blank" rel="nofollow">StemRNA™ clinical seed iPSC manufacturing</a> and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=2696405221&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fgene-editing-services%2Fstemedit%2Fcase-studies&amp;a=StemEdit+gene+editing" target="_blank" rel="nofollow">StemEdit gene editing</a> to <a http://www.streetinsider.com/Press+Releases/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html Tue, 03 Mar 2026 09:00:00 -0400 4978 A.04740540 A.06822034 A.31066700 O.05487715 O.20026344 O.22422661 O.30693798 http://www.streetinsider.com/Press+Releases/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html <div class="xn-content"> <p class="prntac"><i>Integrated Workflow Including Clinical Seed Production </i><i>and StemEdit Gene Editing Services</i></p><p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its <span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> compliant <span>Good Manufacturing Practice (GMP) Master Cell Bank</span> (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its <location value="LU/us.md.bellle" idsrc="xmltag.org" >Beltsville, Maryland</location> facility, <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> now offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=1677481646&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fclinical-stem-cell-services%2Fgmp-ipsc-production&amp;a=StemRNA%E2%84%A2+clinical+seed+iPSC+manufacturing" target="_blank" rel="nofollow">StemRNA™ clinical seed iPSC manufacturing</a> and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=2696405221&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fgene-editing-services%2Fstemedit%2Fcase-studies&amp;a=StemEdit+gene+editing" target="_blank" rel="nofollow">StemEdit gene editing</a> to <a http://www.streetinsider.com/Press+Releases/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html Tue, 03 Mar 2026 09:00:00 -0400 4978 A.04740540 A.06822034 A.31066700 O.05487715 O.20026344 O.22422661 O.30693798 http://www.streetinsider.com/Press+Releases/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html <div class="xn-content"> <p class="prntac"><i>Integrated Workflow Including Clinical Seed Production </i><i>and StemEdit Gene Editing Services</i></p><p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its <span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> compliant <span>Good Manufacturing Practice (GMP) Master Cell Bank</span> (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its <location value="LU/us.md.bellle" idsrc="xmltag.org" >Beltsville, Maryland</location> facility, <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> now offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=1677481646&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fclinical-stem-cell-services%2Fgmp-ipsc-production&amp;a=StemRNA%E2%84%A2+clinical+seed+iPSC+manufacturing" target="_blank" rel="nofollow">StemRNA™ clinical seed iPSC manufacturing</a> and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=2696405221&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fgene-editing-services%2Fstemedit%2Fcase-studies&amp;a=StemEdit+gene+editing" target="_blank" rel="nofollow">StemEdit gene editing</a> to <a http://www.streetinsider.com/Press+Releases/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html Tue, 03 Mar 2026 09:00:00 -0400 4978 A.04740540 A.06822034 A.31066700 O.05487715 O.20026344 O.22422661 O.30693798 http://www.streetinsider.com/Press+Releases/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html <div class="xn-content"> <p class="prntac"><i>Integrated Workflow Including Clinical Seed Production </i><i>and StemEdit Gene Editing Services</i></p><p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its <span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> compliant <span>Good Manufacturing Practice (GMP) Master Cell Bank</span> (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its <location value="LU/us.md.bellle" idsrc="xmltag.org" >Beltsville, Maryland</location> facility, <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> now offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=1677481646&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fclinical-stem-cell-services%2Fgmp-ipsc-production&amp;a=StemRNA%E2%84%A2+clinical+seed+iPSC+manufacturing" target="_blank" rel="nofollow">StemRNA™ clinical seed iPSC manufacturing</a> and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=2696405221&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fgene-editing-services%2Fstemedit%2Fcase-studies&amp;a=StemEdit+gene+editing" target="_blank" rel="nofollow">StemEdit gene editing</a> to <a http://www.streetinsider.com/Press+Releases/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html Tue, 03 Mar 2026 09:00:00 -0400 4978 A.04740540 A.06822034 A.31066700 O.05487715 O.20026344 O.22422661 O.30693798 http://www.streetinsider.com/PRNewswire/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html <div class="xn-content"> <p class="prntac"><i>Integrated Workflow Including Clinical Seed Production </i><i>and StemEdit Gene Editing Services</i></p><p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its <span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> compliant <span>Good Manufacturing Practice (GMP) Master Cell Bank</span> (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its <location value="LU/us.md.bellle" idsrc="xmltag.org" >Beltsville, Maryland</location> facility, <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> now offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=1677481646&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fclinical-stem-cell-services%2Fgmp-ipsc-production&amp;a=StemRNA%E2%84%A2+clinical+seed+iPSC+manufacturing" target="_blank" rel="nofollow">StemRNA™ clinical seed iPSC manufacturing</a> and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=2696405221&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fgene-editing-services%2Fstemedit%2Fcase-studies&amp;a=StemEdit+gene+editing" target="_blank" rel="nofollow">StemEdit gene editing</a> to <a http://www.streetinsider.com/PRNewswire/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html Tue, 03 Mar 2026 09:00:00 -0400 4978 A.04740540 A.06822034 A.31066700 O.05487715 O.20026344 O.22422661 O.30693798 http://www.streetinsider.com/PRNewswire/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html <div class="xn-content"> <p class="prntac"><i>Integrated Workflow Including Clinical Seed Production </i><i>and StemEdit Gene Editing Services</i></p><p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its <span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> compliant <span>Good Manufacturing Practice (GMP) Master Cell Bank</span> (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its <location value="LU/us.md.bellle" idsrc="xmltag.org" >Beltsville, Maryland</location> facility, <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> now offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=1677481646&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fclinical-stem-cell-services%2Fgmp-ipsc-production&amp;a=StemRNA%E2%84%A2+clinical+seed+iPSC+manufacturing" target="_blank" rel="nofollow">StemRNA™ clinical seed iPSC manufacturing</a> and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=2696405221&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fgene-editing-services%2Fstemedit%2Fcase-studies&amp;a=StemEdit+gene+editing" target="_blank" rel="nofollow">StemEdit gene editing</a> to <a http://www.streetinsider.com/PRNewswire/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html Tue, 03 Mar 2026 09:00:00 -0400 4978 A.04740540 A.06822034 A.31066700 O.05487715 O.20026344 O.22422661 O.30693798 http://www.streetinsider.com/PRNewswire/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html <div class="xn-content"> <p class="prntac"><i>Integrated Workflow Including Clinical Seed Production </i><i>and StemEdit Gene Editing Services</i></p><p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its <span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> compliant <span>Good Manufacturing Practice (GMP) Master Cell Bank</span> (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its <location value="LU/us.md.bellle" idsrc="xmltag.org" >Beltsville, Maryland</location> facility, <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> now offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=1677481646&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fclinical-stem-cell-services%2Fgmp-ipsc-production&amp;a=StemRNA%E2%84%A2+clinical+seed+iPSC+manufacturing" target="_blank" rel="nofollow">StemRNA™ clinical seed iPSC manufacturing</a> and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=2696405221&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fgene-editing-services%2Fstemedit%2Fcase-studies&amp;a=StemEdit+gene+editing" target="_blank" rel="nofollow">StemEdit gene editing</a> to <a http://www.streetinsider.com/PRNewswire/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html Tue, 03 Mar 2026 09:00:00 -0400 4978 A.04740540 A.06822034 A.31066700 O.05487715 O.20026344 O.22422661 O.30693798 http://www.streetinsider.com/PRNewswire/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html <div class="xn-content"> <p class="prntac"><i>Integrated Workflow Including Clinical Seed Production </i><i>and StemEdit Gene Editing Services</i></p><p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its <span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> compliant <span>Good Manufacturing Practice (GMP) Master Cell Bank</span> (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its <location value="LU/us.md.bellle" idsrc="xmltag.org" >Beltsville, Maryland</location> facility, <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> now offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=1677481646&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fclinical-stem-cell-services%2Fgmp-ipsc-production&amp;a=StemRNA%E2%84%A2+clinical+seed+iPSC+manufacturing" target="_blank" rel="nofollow">StemRNA™ clinical seed iPSC manufacturing</a> and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=2696405221&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fgene-editing-services%2Fstemedit%2Fcase-studies&amp;a=StemEdit+gene+editing" target="_blank" rel="nofollow">StemEdit gene editing</a> to <a http://www.streetinsider.com/PRNewswire/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html Tue, 03 Mar 2026 09:00:00 -0400 4978 A.04740540 A.06822034 A.31066700 O.05487715 O.20026344 O.22422661 O.30693798 http://www.streetinsider.com/PRNewswire/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html <div class="xn-content"> <p class="prntac"><i>Integrated Workflow Including Clinical Seed Production </i><i>and StemEdit Gene Editing Services</i></p><p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its <span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> compliant <span>Good Manufacturing Practice (GMP) Master Cell Bank</span> (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its <location value="LU/us.md.bellle" idsrc="xmltag.org" >Beltsville, Maryland</location> facility, <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> now offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=1677481646&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fclinical-stem-cell-services%2Fgmp-ipsc-production&amp;a=StemRNA%E2%84%A2+clinical+seed+iPSC+manufacturing" target="_blank" rel="nofollow">StemRNA™ clinical seed iPSC manufacturing</a> and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=2696405221&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fgene-editing-services%2Fstemedit%2Fcase-studies&amp;a=StemEdit+gene+editing" target="_blank" rel="nofollow">StemEdit gene editing</a> to <a http://www.streetinsider.com/PRNewswire/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html Tue, 03 Mar 2026 09:00:00 -0400 4978 A.04740540 A.06822034 A.31066700 O.05487715 O.20026344 O.22422661 O.30693798 http://www.streetinsider.com/PRNewswire/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html <div class="xn-content"> <p class="prntac"><i>Integrated Workflow Including Clinical Seed Production </i><i>and StemEdit Gene Editing Services</i></p><p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its <span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> compliant <span>Good Manufacturing Practice (GMP) Master Cell Bank</span> (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its <location value="LU/us.md.bellle" idsrc="xmltag.org" >Beltsville, Maryland</location> facility, <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> now offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=1677481646&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fclinical-stem-cell-services%2Fgmp-ipsc-production&amp;a=StemRNA%E2%84%A2+clinical+seed+iPSC+manufacturing" target="_blank" rel="nofollow">StemRNA™ clinical seed iPSC manufacturing</a> and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=2696405221&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fgene-editing-services%2Fstemedit%2Fcase-studies&amp;a=StemEdit+gene+editing" target="_blank" rel="nofollow">StemEdit gene editing</a> to <a http://www.streetinsider.com/PRNewswire/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html Tue, 03 Mar 2026 09:00:00 -0400 4978 A.04740540 A.06822034 A.31066700 O.05487715 O.20026344 O.22422661 O.30693798 http://www.streetinsider.com/PRNewswire/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html <div class="xn-content"> <p class="prntac"><i>Integrated Workflow Including Clinical Seed Production </i><i>and StemEdit Gene Editing Services</i></p><p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its <span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> compliant <span>Good Manufacturing Practice (GMP) Master Cell Bank</span> (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its <location value="LU/us.md.bellle" idsrc="xmltag.org" >Beltsville, Maryland</location> facility, <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> now offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=1677481646&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fclinical-stem-cell-services%2Fgmp-ipsc-production&amp;a=StemRNA%E2%84%A2+clinical+seed+iPSC+manufacturing" target="_blank" rel="nofollow">StemRNA™ clinical seed iPSC manufacturing</a> and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=2696405221&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fgene-editing-services%2Fstemedit%2Fcase-studies&amp;a=StemEdit+gene+editing" target="_blank" rel="nofollow">StemEdit gene editing</a> to <a http://www.streetinsider.com/PRNewswire/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html Tue, 03 Mar 2026 09:00:00 -0400 4978 A.04740540 A.06822034 A.31066700 O.05487715 O.20026344 O.22422661 O.30693798 http://www.streetinsider.com/PRNewswire/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html <div class="xn-content"> <p class="prntac"><i>Integrated Workflow Including Clinical Seed Production </i><i>and StemEdit Gene Editing Services</i></p><p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its <span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> compliant <span>Good Manufacturing Practice (GMP) Master Cell Bank</span> (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its <location value="LU/us.md.bellle" idsrc="xmltag.org" >Beltsville, Maryland</location> facility, <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> now offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=1677481646&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fclinical-stem-cell-services%2Fgmp-ipsc-production&amp;a=StemRNA%E2%84%A2+clinical+seed+iPSC+manufacturing" target="_blank" rel="nofollow">StemRNA™ clinical seed iPSC manufacturing</a> and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629464-1&amp;h=2696405221&amp;u=https%3A%2F%2Fwww.reprocell.com%2Fgene-editing-services%2Fstemedit%2Fcase-studies&amp;a=StemEdit+gene+editing" target="_blank" rel="nofollow">StemEdit gene editing</a> to <a http://www.streetinsider.com/PRNewswire/REPROCELL+Launches+GMP+Master+Cell+Bank+Manufacturing+for+Clinical+iPSCs/26097674.html Tue, 03 Mar 2026 09:00:00 -0400 4978 A.04740540 A.06822034 A.31066700 O.05487715 O.20026344 O.22422661 O.30693798 http://www.streetinsider.com/Press+Releases/REPROCELL+Launches+StemEdit+-+Clinical+Gene+Editing+Services+and+New+iPSC+Lines+Using+AI-Designed+editing+tools/25904998.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.md.bellle" idsrc="xmltag.org" >BELTSVILLE, Md.</location></span>, <span class="legendSpanClass"><chron>Jan. 28, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4978" idsrc="xmltag.org" >REPROCELL</span> today announced the commercial launch of <b>StemEdit</b>, its clinical gene editing services and new gene-edited iPSC product lines leveraging <b>OpenCRISPR-1™, an AI-designed genome editing system</b> licensed from Profluent (<location value="LU/us.ca.emelle" idsrc="xmltag.org" >Emeryville, CA</location>, USA).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <a target="_blank" href="https://mma.prnewswire.com/media/2800592/REPROCELL_USA_Logo.html" target="_blank" http://www.streetinsider.com/Press+Releases/REPROCELL+Launches+StemEdit+-+Clinical+Gene+Editing+Services+and+New+iPSC+Lines+Using+AI-Designed+editing+tools/25904998.html Wed, 28 Jan 2026 09:00:00 -0400 4978 A.04740540 O.05487715 O.30693798